Navigation Links
Cantel Medical Reports 29% Increase in Net Income - EPS of $0.29 vs. $0.23 for Quarter Ended January 31, 2010
Date:3/9/2010

rest expense 339 674 726 1,425 Interest income (8) (38) (16) (108) Depreciation 1,574 1,525 3,138 3,075 Amortization 1,294 1,268 2,572 2,606 Loss on disposal of fixed assets 227 8 227 22 --- --- --- --- EBITDA 11,079 9,400 24,285 18,486 Stock-based compensation expense 811 525 1,600 1,045 --- --- ----- ----- EBITDAS $11,890 $9,925 $25,885 $19,531 ======= ====== ======= ======= EBITDAS is a measure of the Company's performance that is not required by, or presented in accordance with, Generally Accepted Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial measure defined by the Company as income before interest, taxes, depreciation, amortization and stock- based compensation expense. The Company believes EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and depreciation of capital equipment, has on the Company's net income. In particular, acquisitions
'/>"/>
SOURCE Cantel Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2010
2. Cantel Medical Authorizes Semiannual Dividend
3. Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase
4. Cantel Medical Corp. to Hold Conference Call to Discuss Results for its First Quarter Ended October 31, 2009
5. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
6. Cantel Medical Named to the Forbes 2009 List of the 200 Best Small Companies in America
7. Cantel Medicals Crosstex Subsidiary Launches New Specially Treated Face Mask Effective Against H1N1 Influenza
8. Cantel Medical Corp. To Hold Conference Call To Discuss Fourth Quarter and Fiscal 2009 Results
9. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
10. Concentric Medical and the Merci Retrieval System(R) Highlighted at the 2010 International Stroke Conference
11. invendo medical Files 510(K) Notice With FDA for Clearance of the Computer-Assisted Colonoscopy System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... SEATTLE, March 25 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... complete in,the phase III EXTEND (PIX301) clinical trial of ... non-Hodgkin,s lymphoma (NHL).,An analysis of the data is expected ... with the U.S. Food and Drug Administration (FDA) the ...
... Patients to ... Higher Rates of BARACLUDE Resistance -, PRINCETON, N.J., ... a continued low incidence of,resistance in nucleoside-naive patients through ... patients analyzed, no additional,patient developed resistance in the fifth ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 2Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... filed in state and federal litigations since the 2012 ... has surpassed 3,700 filings, Bernstein Liebhard LLP reports. According ... at least 2,064 cases have been filed in the ... Rejuvenate Hip Stem and the ABG II Modular Hip ...
(Date:7/26/2014)... “Today, we introduce our new items ... over the world. All these models are offered at ... the UK market,” says the CEO of the company. ... women’s special occasion outfits. , Ladies have to find ... is one of the best choices for many ladies ...
(Date:7/26/2014)... “BRIC Sinuscopes Market Outlook to 2020,? provides key ... provides value, in millions of US dollars, volume (in ... segments – Rigid Non-Video Sinuscopes. , The report also ... of these market categories, and global corporate-level profiles of ... deals related to the Sinuscopes market wherever available. , ...
(Date:7/26/2014)... According to the Tinnitus ... this is a comprehensive guide that consists ... all types of disorders related to ... due to Ménière's disease ,     Objective ... tinnitus ,     Inner, middle or external ...
(Date:7/26/2014)... New York (PRWEB) July 26, 2014 ... to be filed in U.S. courts, Bernstein Liebhard LLP ... federal health regulators to ban uterine morcellation. According to ... a 46-year-old mother of four from California who was ... cancer called leiomyosarcoma just 10 days after undergoing a ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit Filings in State and Federal Litigations Continue to Rise, Bernstein Liebhard LLP Reports 3Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes New Calls for Ban on Uterine Mocellation In Light of Cancer Risk 4
... of two titles, Journal of Analytical Toxicology ( JAT ... from Preston Publications, in a transaction managed by DeSilva+Phillips. The ... STM journal list published by OUP. "We are ... two titles. They have a rich history and we look forward ...
... HealthDay Reporter , TUESDAY, Dec. 6 (HealthDay News) -- The ... a handy jet at your disposal, but the job also comes ... your life? Maybe not, new research suggests. The data showed ... years off their lives due to the effects of time spent ...
... HOBOKEN, NJ Keeping your brain in shapeno sweat. ... diet is just as important to maintaining mental performance ... are an easy, effective way to manage mental focus, ... antioxidant plant extract from the bark of the French ...
... depressive symptoms following birth also reported intimate partner violence finds ... An International Journal of Obstetrics and Gynaecology . The ... depressive symptoms first reported this at six months after birth ... emotional abuse) in the perinatal period is associated with a ...
... , TUESDAY, Dec. 6 (HealthDay News) -- New ... and when women with certain breast cancers will experience ... forms of breast cancer, are slated to be presented ... The research also revealed that genetic data gleaned ...
... in India are too poor to afford pacemakers. But a ... the devices and implanting them in Indian patients "is very ... Medical Center is a co-author of the study, published online ... . Kulkarni helped conduct the research before coming to Loyola ...
Cached Medicine News:Health News:Oxford University Press acquires 2 journals from Preston Publications 2Health News:Most U.S. Presidents Live Longer Than Their Peers 2Health News:Pycnogenol® found to improve memory and test scores in college students in new clinical trial 2Health News:Depressive symptoms and intimate partner violence in the 12 months after childbirth 2Health News:New Tests Might Better Predict Breast Cancer's Return 2Health News:New Tests Might Better Predict Breast Cancer's Return 3Health News:New Tests Might Better Predict Breast Cancer's Return 4Health News:Reusing pacemakers from deceased patients is safe and effective, study finds 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: